Corvus goes pivotal in peripheral T-cell lymphoma
Dizal and Daiichi have set the bar, but a lack of other interest in ITK inhibition could ring alarm bells.
Regeneron gets another bispecific blow
Meanwhile, recent updates hint at more issues in the group’s pipeline of bispecific MAbs.
Opdualag sets its sights on lung
After several disappointments Bristol at last turns its Lag3/PD-1 combo to first-line lung cancer.
Merck shuffles the Kelun deck again
Claudin18.2 is out, but the US big pharma opts in to a new project.
Pfizer makes haste to go EZ
The company sticks with EZH2, despite others adding EZH1 inhibition.
